Emcure Pharmaceuticals (NSE:EMCURE) Interest Expense: ₹-1,437 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:EMCURE Emcure Pharmaceuticals Ltd NSE:EMCURE
41 GF Score
Price ₹1,924.50
! 5 Warning Signs
View Full Analysis

What is Emcure Pharmaceuticals Interest Expense?

Emcure Pharmaceuticals NSE:EMCURE +3.40% 41 Interest Expense is ₹-1,437 Mil as of Mar. 2026. GuruFocus rates NSE:EMCURE with a GF Score™ of 41/100. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Emcure Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was ₹ -464 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-1,437 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Emcure Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was ₹ 3,792 Mil. Emcure Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was ₹ -464 Mil. Emcure Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 was 8.17. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emcure Pharmaceuticals  (NSE:EMCURE) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emcure Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was ₹-464 Mil. Its Operating Income for the three months ended in Mar. 2026 was ₹3,792 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was ₹5,145 Mil.

Emcure Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*3792.07/-464.01
=8.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Emcure Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Emcure Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emcure Pharmaceuticals Interest Expense Chart

Emcure Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial -1,324.64 -1,629.15 -2,006.91 -1,757.84 -1,436.73

Emcure Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -390.25 -267.55 -325.42 -379.75 -464.01
NSE:EMCURE
41GF Score
Emcure Pharmaceuticals Ltd NSE:EMCURE
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emcure Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1,437 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-1,437 Mil mean?
Emcure Pharmaceuticals (NSE:EMCURE) has a Interest Expense of ₹-1,437 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Emcure Pharmaceuticals and its competitors.
Is Emcure Pharmaceuticals' Interest Expense too high?
Emcure Pharmaceuticals' current Interest Expense is ₹-1,437 Mil. Overall, Emcure Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Emcure Pharmaceuticals' Interest Expense compare to ZTS and UTHR?
Emcure Pharmaceuticals' Interest Expense of ₹-1,437 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Emcure Pharmaceuticals and its competitors. Emcure Pharmaceuticals's current Interest Expense is ₹-1,437 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emcure Pharmaceuticals stock overvalued right now?
Emcure Pharmaceuticals (NSE:EMCURE) has a current Interest Expense of ₹-1,437 Mil. The current Interest Expense is ₹-1,437 Mil. Emcure Pharmaceuticals' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Emcure Pharmaceuticals (NSE:EMCURE), the current Interest Expense is ₹-1,437 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emcure Pharmaceuticals Business Description

Other Exchanges 544210:India
Address Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune, MH, IND, 411 057
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
41GF Score

Get the complete analysis for NSE:EMCURE

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,924.50
Price